Ongoing Research Report
In the News
September 2020: Aliskiren becomes the first direct renin inhibitor to available in the UK launched by Novartis and is licensed either as monotherapy or in combination with other antihypertensives.
Introduction to Renin-Inhibitor
Renin is a proteolytic enzyme that is secreted in response to sympathetic activation, decreased sodium delivery and hypotension by the kidneys to the distal renal tubule. It converts angiotensinogen to angiotensin I, which is later converted to angiotensin II by angiotensin-converting enzyme. Angiotensin II is a potent vasoconstrictor that is responsible for blood pressure to rise. Renin-inhibitors are termed as a group of pharmaceutical drugs used primarily in the treatment of essential hypertension by blocking the activity of renin and causing vasodilatation. The first and second generations of drugs faced problems such as poor bioavailability and lack of potency whereas the third-generation drugs had acceptable oral bioavailability and were potent enough for clinical use. Aliskiren (INN) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Market Size and Forecast
The global renin-inhibitor market is projected to witness a robust growth owing to the rising awareness about hypertension with growing predominance, fixed-dose blending therapies, and escalated epidemic proportions of hypertension. According to the World Health Organization, around 1.13 billion people worldwide are suffering from hypertension, most (two-thirds) living in low- and middle-income countries. Moreover, irregular lifestyle with food habits, changing lifestyle, aging regardless of demography, and supplemented stress level coupled with rising research and development for the modern drugs also supporting the growth of the renin-inhibitor market. However, side effects such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization are estimated to hinder the growth of the global market over the forecast period.
The resin-inhibitor market is anticipated to record a significant CAGR over the forecast period i.e. 2020-2028. The market is segmented by product type & by application, out of which, the age above 66 segment of the application sector is anticipated to hold leading shares in the renin-inhibitor market on account of rising cardiovascular diseases and hypertension cases among this segment. According to the National Centre for Health Statistics. From 2015 to 2016, the prevalence of hypertension was 29.0% and increased with age: age group 18-39, 7.5%; 40-59, 33.2%; and 60 and over, 63.1%. On the contrary, 300mg/tablet segment of the product type sector is estimated to witness modest growth over the forecast period owing to the treatment of high blood pressure by relaxing blood vessels for a better circulation of the blood.
Growth Drivers
Frequency of Cardiovascular Diseases Among the Geriatric Population
The renin-inhibitor market is estimated to observe a significant growth on account of the frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications. Additionally, an individual who suffers from hypertension is very susceptible to other complications such as aneurysm and heart failure. Thus, requires early diagnosis as well as management by using renin-inhibitor drugs.
By Region
Based on geographically, the renin-inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market in North America is anticipated to hold the leading share during the forecast period on account of a rise in the prevalence of hypertension and chronic kidney disorders. Conversely, the presence of major companies propels the renin-inhibitor market growth in the North America region. On the contrary, the Asia-Pacific region is anticipated to witness high growth in the global market over the forecast period owing to the high incidences of cardiovascular diseases, government initiatives taken for the healthcare sector, and high population pool.
The renin-inhibitors market is further classified on the basis of region as follows:
In the News
September 2020: Aliskiren becomes the first direct renin inhibitor to available in the UK launched by Novartis and is licensed either as monotherapy or in combination with other antihypertensives.
Introduction to Renin-Inhibitor
Renin is a proteolytic enzyme that is secreted in response to sympathetic activation, decreased sodium delivery and hypotension by the kidneys to the distal renal tubule. It converts angiotensinogen to angiotensin I, which is later converted to angiotensin II by angiotensin-converting enzyme. Angiotensin II is a potent vasoconstrictor that is responsible for blood pressure to rise. Renin-inhibitors are termed as a group of pharmaceutical drugs used primarily in the treatment of essential hypertension by blocking the activity of renin and causing vasodilatation. The first and second generations of drugs faced problems such as poor bioavailability and lack of potency whereas the third-generation drugs had acceptable oral bioavailability and were potent enough for clinical use. Aliskiren (INN) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Market Size and Forecast
The global renin-inhibitor market is projected to witness a robust growth owing to the rising awareness about hypertension with growing predominance, fixed-dose blending therapies, and escalated epidemic proportions of hypertension. According to the World Health Organization, around 1.13 billion people worldwide are suffering from hypertension, most (two-thirds) living in low- and middle-income countries. Moreover, irregular lifestyle with food habits, changing lifestyle, aging regardless of demography, and supplemented stress level coupled with rising research and development for the modern drugs also supporting the growth of the renin-inhibitor market. However, side effects such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization are estimated to hinder the growth of the global market over the forecast period.
The resin-inhibitor market is anticipated to record a significant CAGR over the forecast period i.e. 2020-2028. The market is segmented by product type & by application, out of which, the age above 66 segment of the application sector is anticipated to hold leading shares in the renin-inhibitor market on account of rising cardiovascular diseases and hypertension cases among this segment. According to the National Centre for Health Statistics. From 2015 to 2016, the prevalence of hypertension was 29.0% and increased with age: age group 18-39, 7.5%; 40-59, 33.2%; and 60 and over, 63.1%. On the contrary, 300mg/tablet segment of the product type sector is estimated to witness modest growth over the forecast period owing to the treatment of high blood pressure by relaxing blood vessels for a better circulation of the blood.
Growth Drivers
Frequency of Cardiovascular Diseases Among the Geriatric Population
The renin-inhibitor market is estimated to observe a significant growth on account of the frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications. Additionally, an individual who suffers from hypertension is very susceptible to other complications such as aneurysm and heart failure. Thus, requires early diagnosis as well as management by using renin-inhibitor drugs.
By Region
Based on geographically, the renin-inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market in North America is anticipated to hold the leading share during the forecast period on account of a rise in the prevalence of hypertension and chronic kidney disorders. Conversely, the presence of major companies propels the renin-inhibitor market growth in the North America region. On the contrary, the Asia-Pacific region is anticipated to witness high growth in the global market over the forecast period owing to the high incidences of cardiovascular diseases, government initiatives taken for the healthcare sector, and high population pool.
The renin-inhibitors market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Companies Mentioned
- Pfizer
- Bio-Rad Laboratories Inc.
- Sanofi
- Lupin
- Merck & Co.
- Astra Zeneca
- Daiichi Sankyo
- Novartis
- Boehringer Ingelheim International GmbH
- Johnson & Johnson
- Other Notable Players
Please note the number of players as well as the addition/deletion can be done in the final deliverable as per the feasibility
